The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects. Molecular profiling has allowed therapy to be tailored for an individual patient to some extent. However, further molecular studies are needed to individualize the choice and length of adjuvant hormone therapy. Ongoing studies are evaluating the role of additional targeted therapies, such as CDK4/6 inhibitors, to further improve outcome for patients with early-stage hormone receptor-positive breast cancer.
CITATION STYLE
Shah, R., & O’Regan, R. M. (2018). Adjuvant endocrine therapy. In Cancer Treatment and Research (Vol. 173, pp. 15–29). Springer International Publishing. https://doi.org/10.1007/978-3-319-70197-4_2
Mendeley helps you to discover research relevant for your work.